N-(6-hydroxyhexyl)acridine-4-carboxamide | 142038-96-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(6-hydroxyhexyl)acridine-4-carboxamide
• 英文别名: N-(6-Hydroxyhexyl)-4-acridinecarboxamide
• CAS: 142038-96-8
• 化学式: C₂₀H₂₂N₂O₂
• 分子量: 322.407
• InChiKey: WGWFFHQBAWNYOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(6-hydroxyhexyl)acridine-4-carboxamide 在 吡啶 作用下， 以 吡啶 为溶剂， 反应 20.5h， 生成 Acridine-4-carboxylic acid [6-(2-amino-ethylamino)-hexyl]-amide
  参考文献：
  名称：

  DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II)

  摘要：

  A series of acridine-2- and -4-carboxamide-linked analogues of PtenCl2 has been prepared and evaluated for biological activity against several tumor cell lines in vitro and in vivo. The platinum complexes were generally more cytotoxic than the corresponding ligands against wild-type P388 leukemia cells in vitro, with acridine-4-carboxamide complexes being the more effective. In contrast to cisplatin and PtenCl2, the complexes were equally active in vitro against both wild-type and cisplatin-resistant P388 lines. The 4-carboxamide complexes showed high levels of in vivo activity (ILS >100%) against wild-type P388 using a single-dose protocol, and one compound was also significantly active in vivo in a cisplatin-resistant line, against which cisplatin and PtenCl2 are inactive.

  DOI：

  10.1021/jm00094a008
• 作为产物：
  描述：

  4-吖啶羧酸 、 6-氨基-1-己醇 在 N,N'-羰基二咪唑 作用下， 生成 N-(6-hydroxyhexyl)acridine-4-carboxamide
  参考文献：
  名称：

  DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II)

  摘要：

  A series of acridine-2- and -4-carboxamide-linked analogues of PtenCl2 has been prepared and evaluated for biological activity against several tumor cell lines in vitro and in vivo. The platinum complexes were generally more cytotoxic than the corresponding ligands against wild-type P388 leukemia cells in vitro, with acridine-4-carboxamide complexes being the more effective. In contrast to cisplatin and PtenCl2, the complexes were equally active in vitro against both wild-type and cisplatin-resistant P388 lines. The 4-carboxamide complexes showed high levels of in vivo activity (ILS >100%) against wild-type P388 using a single-dose protocol, and one compound was also significantly active in vivo in a cisplatin-resistant line, against which cisplatin and PtenCl2 are inactive.

  DOI：

  10.1021/jm00094a008

文献信息

• Synthesis and biological activity of ester derivatives of mycophenolic acid and acridines/acridones as potential immunosuppressive agents
  作者：Grzegorz Cholewinski、Dorota Iwaszkiewicz-Grzes、Piotr Trzonkowski、Krystyna Dzierzbicka

  DOI：10.3109/14756366.2015.1077821

  日期：2016.11.1

  Improved derivatives of mycophenolic acid (MPA) are necessary to reduce the frequency of adverse effects, this drug exerts in treated patients. In this study, MPA was coupled with N-(ω-hydroxyalkyl)-9-acridone-4-carboxamides or N-(ω-hydroxyalkyl)acridine-4-carboxamides to give respective ester conjugates upon Yamaguchi protocol. This esterification required protection of phenol group in MPA. Designed

  麦考酚酸（MPA）的改良衍生物对于减少这种药物在治疗患者中产生的不良反应的发生率是必不可少的。在这项研究中，MPA与N-（ω-羟烷基）-9-ac啶酮-4-羧酰胺或N-（ω-羟烷基）ac啶-4-羧酰胺偶联后，根据Yamaguchi方案生成相应的酯共轭物。这种酯化作用需要保护MPA中的酚基。设计的结合物显示出比母体MPA更高的体外效价。cr啶衍生物比a啶酮类似物更具活性，MPA和杂环单元之间的烷基接头长度会影响所观察到的细胞毒性。衍生物2b，2d，3a，3b显示出最有希望的免疫抑制活性。
• DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II)
  作者：Ho H. Lee、Brian D. Palmer、Bruce C. Baguley、Michael Chin、W. David McFadyen、Geoffrey Wickham、Deborah Thorsbourne-Palmer、Laurence P. G. Wakelin、William A. Denny

  DOI：10.1021/jm00094a008

  日期：1992.8

  A series of acridine-2- and -4-carboxamide-linked analogues of PtenCl2 has been prepared and evaluated for biological activity against several tumor cell lines in vitro and in vivo. The platinum complexes were generally more cytotoxic than the corresponding ligands against wild-type P388 leukemia cells in vitro, with acridine-4-carboxamide complexes being the more effective. In contrast to cisplatin and PtenCl2, the complexes were equally active in vitro against both wild-type and cisplatin-resistant P388 lines. The 4-carboxamide complexes showed high levels of in vivo activity (ILS >100%) against wild-type P388 using a single-dose protocol, and one compound was also significantly active in vivo in a cisplatin-resistant line, against which cisplatin and PtenCl2 are inactive.